-+ 0.00%
-+ 0.00%
-+ 0.00%

Jazz partners with AbCellera on T-cell engager antibody discovery for solid tumors

PUBT·06/17/2026 13:00:07
Listen to the news
Jazz partners with AbCellera on T-cell engager antibody discovery for solid tumors
  • Jazz entered a preclinical collaboration with AbCellera to discover T-cell engaging multispecific antibodies for GI cancers and other solid tumors.
  • AbCellera will run discovery for two initial programs, with a commitment to start a third within 12 months.
  • Upfront payments total USD 56 million for the first two programs, with another USD 28 million due when the third starts.
  • Jazz holds exclusive options to develop and commercialize resulting antibodies, with worldwide rights upon option exercise.
  • AbCellera could receive up to USD 792 million per program in option fees and milestones, with tiered royalties on net sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.